Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Post- Acute Sequelae of SARS-CoV-2 (PASC)/Long COVID Seminar Series Whitepaper

[1]  S. Farhadian,et al.  Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin , 2022, Biological Psychiatry.

[2]  I. Koralnik,et al.  T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID , 2022, medRxiv.

[3]  J. Howland,et al.  After the virus has cleared—Can preclinical models be employed for Long COVID research? , 2022, PLoS pathogens.

[4]  C. D. Dela Cruz,et al.  Distinguishing features of long COVID identified through immune profiling , 2022, Nature.

[5]  J. Laurence,et al.  Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches , 2022, The Journal of clinical investigation.

[6]  A. Iwasaki,et al.  Unexplained post-acute infection syndromes , 2022, Nature Medicine.

[7]  J. Carette,et al.  Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections. , 2022, Research square.

[8]  Inyoul Y. Lee,et al.  Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.

[9]  C. Campen,et al.  Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , 2021, Medicina.

[10]  S. Pittaluga,et al.  SARS-CoV-2 infection and persistence throughout the human body and brain , 2021 .

[11]  L. Notarangelo,et al.  Temporal Dynamics of Anti–Type 1 Interferon Autoantibodies in Patients With Coronavirus Disease 2019 , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[12]  A. L. Tan,et al.  Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. , 2021, The Lancet. Respiratory medicine.

[13]  P. Ravaud,et al.  Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France , 2021, SSRN Electronic Journal.

[14]  M. Peluso,et al.  Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. , 2021, The Journal of infectious diseases.

[15]  F. Rubino,et al.  Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged ≥18 Years — Long Beach, California, April 1–December 10, 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[16]  T. Iwashyna,et al.  Continuing Cardiopulmonary Symptoms, Disability, and Financial Toxicity 1 Month After Hospitalization for Third-Wave COVID-19: Early Results From a US Nationwide Cohort. , 2021, Journal of hospital medicine.

[17]  M. Peluso,et al.  Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms , 2021, Cell Reports.

[18]  Ting Yu,et al.  1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study , 2021, The Lancet.

[19]  Mark M. Davis,et al.  Systems vaccinology of the BNT162b2 mRNA vaccine in humans , 2021, Nature.

[20]  J. Kolls,et al.  SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes , 2021, JCI insight.

[21]  S. Carsons,et al.  Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients , 2021, European Respiratory Journal.

[22]  L. Dölken,et al.  SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro , 2021, Frontiers in Cellular and Infection Microbiology.

[23]  Xiaoming Zhang,et al.  From blood to tissue: take a deeper look at B cells in lupus , 2021, Cellular & Molecular Immunology.

[24]  J. Saez-Rodriguez,et al.  Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions , 2021, Immunity.

[25]  M. Giacca,et al.  SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care , 2021, Nature Communications.

[26]  C. Chan,et al.  Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19 , 2021, Gut.

[27]  D. Hurley,et al.  Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation , 2021, Pathogens.

[28]  Christopher T. Chan,et al.  Nephrologist Follow-Up versus Usual Care after an Acute Kidney Injury Hospitalization (FUSION): A Randomized Controlled Trial , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[29]  Kevin N. Heath,et al.  Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study , 2021, BMJ.

[30]  S. Rosenkranz,et al.  Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study , 2021, The Lancet Regional Health - Europe.

[31]  S. Nemati,et al.  Artificial intelligence sepsis prediction algorithm learns to say “I don’t know” , 2021, npj Digital Medicine.

[32]  A. Ginde,et al.  Association Between Hyperoxia, Supplemental Oxygen, and Mortality in Critically Injured Patients , 2021, Critical care explorations.

[33]  S. Suskauer,et al.  Adolescent and Young Adult ME/CFS After Confirmed or Probable COVID-19 , 2021, Frontiers in Medicine.

[34]  G. Wallukat,et al.  Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms , 2021, Journal of Translational Autoimmunity.

[35]  Lanjuan Li,et al.  Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features , 2021, Communications biology.

[36]  Lanjuan Li,et al.  Alterations in the human oral and gut microbiomes and lipidomics in COVID-19 , 2021, Gut.

[37]  Ryan D. Chow,et al.  Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms , 2021, Cell Reports Medicine.

[38]  W. Lim,et al.  Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol , 2021, The Lancet Regional Health - Europe.

[39]  M. Mikkelsen,et al.  The Intersection of Health and Critical Illness: Preservation and Restoration , 2021, American journal of respiratory and critical care medicine.

[40]  M. Krousel‐Wood,et al.  Clinical characteristics and outcomes in women and men hospitalized for coronavirus disease 2019 in New Orleans , 2021, Biology of sex differences.

[41]  A. Stenzinger,et al.  SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas , 2021, Nature Metabolism.

[42]  E. Wherry,et al.  New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19 , 2021, medRxiv.

[43]  C. Iacobuzio-Donahue,et al.  Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients , 2021, Cancer Cell.

[44]  G. Hajcak,et al.  Increases in depression and anxiety symptoms in adolescents and young adults during the COVID-19 pandemic , 2021, Psychological Medicine.

[45]  K. Chow,et al.  Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 , 2021, Gut.

[46]  S. Raha,et al.  ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy , 2021, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.

[47]  R. Balk,et al.  COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions , 2021, mBio.

[48]  D. Perl,et al.  Microvascular Injury in the Brains of Patients with Covid-19 , 2020, The New England journal of medicine.

[49]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2020, EClinicalMedicine.

[50]  E. Eskandar,et al.  Neurologic Syndromes Predict Higher In-Hospital Mortality in COVID-19 , 2020, Neurology.

[51]  Elizabeth B White,et al.  Diverse Functional Autoantibodies in Patients with COVID-19 , 2020, Nature.

[52]  C. Conrad,et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.

[53]  H. Dweep,et al.  Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients , 2021, Frontiers in Immunology.

[54]  Diane C. Saunders,et al.  SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in β Cells , 2020, Cell Metabolism.

[55]  C. Rentsch,et al.  Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index , 2020, PloS one.

[56]  Paul J. Harrison,et al.  Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA , 2020, The Lancet Psychiatry.

[57]  M. Nussenzweig,et al.  Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.

[58]  J. Knight,et al.  Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 , 2020, Science Translational Medicine.

[59]  Chun Jimmie Ye,et al.  Global Absence and Targeting of Protective Immune States in Severe COVID-19 , 2020, bioRxiv.

[60]  Mark M. Davis,et al.  Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 , 2020, Cell.

[61]  I. Sanz,et al.  Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19 , 2020 .

[62]  Peter J Hellyer,et al.  Cognitive deficits in people who have recovered from COVID-19 , 2020, EClinicalMedicine.

[63]  William T. Hu,et al.  Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 , 2020, Nature Immunology.

[64]  K. Melmed,et al.  A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City , 2020, Neurology.

[65]  M. Aepfelbacher,et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.

[66]  E. Aronica,et al.  Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study , 2020, The Lancet Microbe.

[67]  T. Ueland,et al.  Elevated markers of gut leakage and inflammasome activation in COVID‐19 patients with cardiac involvement , 2020, Journal of internal medicine.

[68]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[69]  Melanie K. T. Takarangi,et al.  Why the COVID-19 pandemic is a traumatic stressor , 2020, bioRxiv.

[70]  S. Loosen,et al.  Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. , 2020, Journal of the American Society of Nephrology : JASN.

[71]  J. Baehring,et al.  Lessons from a neurology consult service for patients with COVID-19 , 2020, The Lancet Neurology.

[72]  S. Galea,et al.  Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic , 2020, JAMA network open.

[73]  N. Marrouche,et al.  Metabolic Syndrome and COVID-19 Mortality Among Adult Black Patients in New Orleans , 2020, Diabetes care.

[74]  P. Horby,et al.  Core Outcomes Set for Trials in People With Coronavirus Disease 2019 , 2020, Critical care medicine.

[75]  K. Khunti,et al.  Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study , 2020, The Lancet Diabetes & Endocrinology.

[76]  T. Caza,et al.  COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19 , 2020, Nature Reviews Nephrology.

[77]  J. Lefante,et al.  BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans , 2020, Obesity.

[78]  F. Ovalle,et al.  METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES , 2020, medRxiv.

[79]  Zigui Chen,et al.  Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19 , 2020, Gut.

[80]  F. Mauvais-Jarvis.  Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19 , 2020, Diabetes.

[81]  K. Wilson,et al.  Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) , 2020, medRxiv.

[82]  David R. Holtgrave,et al.  Assessing racial and ethnic disparities using a COVID-19 outcomes continuum for New York State , 2020, Annals of Epidemiology.

[83]  A. Kotanidou,et al.  Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19 , 2020, Annals of the Rheumatic Diseases.

[84]  S. Klein,et al.  Considering how biological sex impacts immune responses and COVID-19 outcomes , 2020, Nature Reviews Immunology.

[85]  S. Klein,et al.  Biological sex impacts COVID-19 outcomes , 2020, PLoS pathogens.

[86]  S. Farhadian,et al.  Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. , 2020, JAMA neurology.

[87]  E. Price-Haywood,et al.  Hospitalization and Mortality among Black Patients and White Patients with Covid-19 , 2020, The New England journal of medicine.

[88]  S. Ng,et al.  Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization , 2020, Gastroenterology.

[89]  Paolo Fusar-Poli,et al.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[90]  Feng Gao,et al.  Obesity Is a Risk Factor for Greater COVID-19 Severity , 2020, Diabetes Care.

[91]  Victor G. Puelles,et al.  Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.

[92]  Fang Lei,et al.  Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.

[93]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[94]  Can Hou,et al.  Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID‐19 , 2020, Clinical and translational science.

[95]  F. Verheugt,et al.  Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography , 2020, Clinical neurophysiology practice.

[96]  D. Leaf,et al.  Soluble Urokinase Receptor and Acute Kidney Injury. , 2020, The New England journal of medicine.

[97]  Jian Cai,et al.  uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. , 2019, The Journal of clinical investigation.

[98]  D. Landsittel,et al.  Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. , 2019, Journal of the American Society of Nephrology : JASN.

[99]  Sushrut S. Waikar,et al.  The single-cell transcriptomic landscape of early human diabetic nephropathy , 2019, Proceedings of the National Academy of Sciences.

[100]  Colleen L. Marden,et al.  Impaired Health-Related Quality of Life in Adolescent Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Impact of Core Symptoms , 2019, Front. Pediatr..

[101]  L. Montaner,et al.  Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy , 2018, Journal of leukocyte biology.

[102]  K. Kalantar-Zadeh,et al.  Association of the frequency of pre-end-stage renal disease medical care with post-end-stage renal disease mortality and hospitalization , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[103]  F. Verheugt,et al.  Cerebral blood flow changes during tilt table testing in healthy volunteers, as assessed by Doppler imaging of the carotid and vertebral arteries , 2018, Clinical neurophysiology practice.

[104]  A. Forbes,et al.  Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis , 2018, United European gastroenterology journal.

[105]  C. Scarborough.  It's Not Me It's You , 2017 .

[106]  A. Quyyumi,et al.  Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study , 2017, Kidney international reports.

[107]  Jin-Mann S. Lin,et al.  CDC Grand Rounds: Chronic Fatigue Syndrome - Advancing Research and Clinical Education. , 2016, MMWR. Morbidity and mortality weekly report.

[108]  D. Scadden,et al.  Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease , 2016, Nature Medicine.

[109]  P. Almgren,et al.  Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study , 2016, Kidney international reports.

[110]  A. Quyyumi,et al.  Soluble Urokinase Receptor and Chronic Kidney Disease. , 2015, The New England journal of medicine.

[111]  D. Needham,et al.  Posttraumatic Stress Disorder in Critical Illness Survivors: A Metaanalysis* , 2015, Critical care medicine.

[112]  P. Magnus,et al.  Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012 , 2014, BMC Medicine.

[113]  Mark S. Anderson,et al.  Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. , 2013, The Journal of clinical investigation.

[114]  Nicole M. Benson,et al.  Insurance and racial differences in long-term acute care utilization after critical illness* , 2012, Critical care medicine.

[115]  E. Salido,et al.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.

[116]  S. Holland,et al.  Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. , 2010, The Lancet. Infectious diseases.

[117]  Colin W. Key,et al.  Risk factors for depression and anxiety in survivors of acute respiratory distress syndrome. , 2010, General hospital psychiatry.

[118]  Renée R Taylor,et al.  Chronic Fatigue Syndrome After Infectious Mononucleosis in Adolescents , 2009, Pediatrics.

[119]  J. Sterne,et al.  Association between school absence and physical function in paediatric chronic fatigue syndrome/myalgic encephalopathy , 2008, Archives of Disease in Childhood.

[120]  J. Lünemann,et al.  Epstein-Barr virus and multiple sclerosis , 2007 .

[121]  K. Wu,et al.  Posttraumatic Stress after SARS , 2005, Emerging infectious diseases.

[122]  Karen J. Chan,et al.  Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. , 2005, American journal of respiratory and critical care medicine.

[123]  B. Brenner,et al.  Why is proteinuria an ominous biomarker of progressive kidney disease? , 2004, Kidney international. Supplement.

[124]  Arthur S Slutsky,et al.  One-year outcomes in survivors of the acute respiratory distress syndrome. , 2003, The New England journal of medicine.

[125]  K. E. Lucas,et al.  Cerebral and Systemic Hemodynamics Changes During Upright Tilt in Chronic Fatigue Syndrome , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[126]  B. Cohen,et al.  Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. , 2002, The Journal of pediatrics.

[127]  P. Sullivan,et al.  A Twin Study of Chronic Fatigue , 2001, Psychosomatic medicine.

[128]  H. Calkins,et al.  Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. , 1999, The Journal of pediatrics.

[129]  E. Bigler,et al.  Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. , 1999, American journal of respiratory and critical care medicine.

[130]  H. Calkins,et al.  The relationship between neurally mediated hypotension and the chronic fatigue syndrome. , 1995, JAMA.

[131]  H. Calkins,et al.  Is neurally mediated hypotension an unrecognised cause of chronic fatigue? , 1995, The Lancet.

[132]  G. Poudel,et al.  Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection A Systematic Review , 2021 .

[133]  G. Lauc,et al.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis , 2019, Current HIV/AIDS Reports.

[134]  O. Dekkers,et al.  [Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis]. , 2015, Nederlands tijdschrift voor geneeskunde.

[135]  J. Nicoli,et al.  Pretreatment with citrulline improves gut barrier after intestinal obstruction in mice. , 2012, JPEN. Journal of parenteral and enteral nutrition.

[136]  P. Carmeliet,et al.  Modification of kidney barrier function by the urokinase receptor , 2008, Nature Medicine.

[137]  Jeannie-Marie S. Leoutsakos,et al.  Fatigue Symptoms During the First Year Following ARDS , 2022 .